Inês N. Alves

Inês N. Alves

Auto-generated profile, based on publicly available information

Inês N. Alves

University of Porto

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Ana DuarteAna Duarte
Ana Duarte
ECEmanuel Candeias
Emanuel Candeias
IAInês N. Alves
Inês N. Alves
DMDébora Tatiana Sousa Mena
Débora Tatiana Sousa Mena
Daniela Franco da SilvaDaniela Franco da Silva
Daniela Franco da Silva
Paula I. MoreiraPaula I. Moreira
Paula I. Moreira
Alzheimer’s disease (AD) is the most common form of dementia worldwide, being characterized by the deposition of senile plaques, neurofibrillary tangles (enriched in the amyloid beta (Aβ) peptide and hyperphosphorylated tau (p-tau), respectively) and memory loss. Aging, type 2 diabetes (T2D) and female sex (especially after menopause) are risk factors for AD, but their crosslinking mechanisms remain unclear. Most clinical trials targeting AD neuropathology failed and it remains incurable. However, evidence suggests that effective anti-T2D drugs, such as the GLP-1 mimetic and neuroprotector liraglutide, can be also efficient against AD. Thus, we aimed to study the benefits of a peripheral liraglutide treatment in AD female mice. We used blood and brain cortical lysates from 10-month-old 3xTg-AD female mice, treated for 28 days with liraglutide (0.2 mg/kg, once/day) to evaluate parameters affected in AD (e.g., Aβ and p-tau, motor and cognitive function, glucose metabolism, inflammation and oxidative/nitrosative stress). Despite the limited signs of cognitive changes in mature female mice, liraglutide only reduced their cortical Aβ1–42 levels. Liraglutide partially attenuated brain estradiol and GLP-1 and activated PKA levels, oxidative/nitrosative stress and inflammation in these AD female mice. Our results support the earlier use of liraglutide as a potential preventive/therapeutic agent against the accumulation of the first neuropathological features of AD in females.

3 April 2025 in The Journal of Physiology
Verified
Journal Article
Closed access
AGAlexandre Gonçalves
Alexandre Gonçalves
IAInês N. Alves
Inês N. Alves
CMCláudia Mendes
Cláudia Mendes
DMDaniela Miranda
Daniela Miranda
GCGlória Conceição
Glória Conceição
IFInês Falcão-Pires
Inês Falcão-Pires

2 March 2024 in Biology
Verified
Journal Article
Open access
PDF file
Isabella Coraini BracchiIsabella Coraini Bracchi
Isabella Coraini Bracchi
JMJuliana Morais
Juliana Morais
JCJoão Almeida Coelho
João Almeida Coelho
AFAna Filipa Ferreira
Ana Filipa Ferreira
IAInês Alves
Inês Alves
RNRita Negrão
Rita Negrão
The consumption of non-sugar sweeteners (NSS) has increased during pregnancy. The European Food Safety Agency suggested that steviol glycosides, such as Rebaudioside A (RebA), the major sweetener component of stevia, are safe for humans up to a dose of 4 mg/kg body weight/day. However, the World Health Organization recommended in 2023 the restraint of using NSS, including stevia, at any life stage, highlighting the need to study NSS safety in early periods of development. We aimed to study the mitochondrial and cardiometabolic effects of long-term RebA consumption during the reproductive stage of the life cycle. Female rats were exposed to RebA (4 mg steviol equivalents/kg body weight/day) in the drinking water from 4 weeks before mating until weaning. Morphometry, food and water consumption, glucose and lipid homeostasis, heart structure, function, and mitochondrial function were assessed. RebA showed an atrophic effect in the heart, decreasing cardiomyocyte cross-sectional area and myocardial fibrosis without repercussions on cardiac function. Mitochondrial and myofilamentary functions were not altered. Glucose tolerance and insulin sensitivity were not affected, but fasting glycemia and total plasma cholesterol decreased. This work suggests that this RebA dose is safe for female consumption during the reproductive stage, from a cardiometabolic perspective. However, studies on the effects of RebA exposure on the offspring are mandatory.

27 June 2026 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
AGAlexandre Gonçalves
Alexandre Gonçalves
ECElaine Zhelan Chen
Elaine Zhelan Chen
HRHosna Rastegarpouyani
Hosna Rastegarpouyani
AFAurélia Araújo Fernandes
Aurélia Araújo Fernandes
IAInês N. Alves
Inês N. Alves
Maicon Landim-VieiraMaicon Landim-Vieira
Maicon Landim-Vieira
Pathogenic variants in desmoglein-2 ( DSG2) are a major cause of arrhythmogenic cardiomyopathy (ACM), a disease plagued by ventricular arrhythmias, contractile dysfunction, myocardial inflammation, and fibrofatty remodeling. Additionally, increasing evidence implicates mitochondrial dysfunction in DSG2-associated disease. However, whether mitochondrial remodeling occurs uniformly across ventricles remains less well defined. Here, we utilized a homozygous Dsg2 mutant ( Dsg2 mut/mut ) mouse to define chamber-specific mitochondrial remodeling in DSG2-linked ACM. Re-analysis of our previously generated cardiomyocyte snRNAseq dataset revealed broad downregulation of mitochondrial transcripts involved in fusion/fission dynamics, calcium handling, mitophagy, structural organization, and electron transport chain (ETC) assembly, findings that are consistent with impaired mitochondrial homeostasis and bioenergetic capacity. Ultrastructural analyses by transmission electron microscopy showed that Dsg2 mut/mut hearts contained an increased number of mitochondria, which were smaller, irregularly shaped, and more disorganized than wildtype (WT) counterparts. Importantly, these alterations were chamber-dependent, with the right ventricle (RV) displaying more pronounced reductions in mitochondrial circularity and greater mitochxondrial abundance than the left ventricle (LV), indicating increased RV susceptibility. Together, these findings unveil mitochondrial remodeling as a feature of DSG2-deficiency and support a desmosomal-mitochondrial axis in ACM pathogenesis, further supporting mitochondrial pathways as candidate therapeutic targets.